9 results for tag: drug prices
Pharmaceutical companies are charging the NHS half a billion pounds a year for cancer treatments discovered with the help of public money. We are paying twice for new medicines. Figures released by the Missing Medicines coalition today (World Cancer Day) show that 3 out of the 5 most expensive cancer medicines brought by ...
A new medical study has found that the latest new cancer drugs are being sold for many times the costs spent developing them; resulting in mega profits for the drug companies who own them and restricted access to these drugs for only the wealthiest patients and healthcare providers.
When we give money to cancer research charities like Cancer Research UK we expect that money to be used efficiently but less than 2% is likely to be spent on researching new drugs that can be given to NHS cancer patients as a routine treatment.
Our medical R&D system is undermining our health – reform could boost our economy and our wellbeing. It’s time we implemented a new, more efficient, collaboratively driven, open innovation model with patient needs at its heart.
The British public pays £2.5bn a year towards the cost of developing new drugs for cancer, but 95% of cancer research discoveries don't work in patients and half of the 5% that do the NHS can't afford. Is this money well spent?
The cost of developing new cancer drugs could be halved at least if we cooperated across the world to publicly fund R&D, using cheaper finance, eliminating wasteful duplication and developing drugs for public benefit not for profit.
The Cancer Drugs Fund was put forward by David Cameron during the 2010 General Election campaign – a tempting olive branch for many cancer patients desperate for expensive life-saving drugs but in reality a short-sighted, vote-winning gesture that has helped to make drugs even more unaffordable in the longer term.
A shocking new study has revealed pharmaceutical companies have been fined more than £25bn over the last 25 years for illegal activity aimed at boosting profits. Patients are ultimately paying the price for this through higher drug prices.
News about a promising new breast cancer treatment combining Herceptin and Tyverb is dampened by the prospect that the drugs may be too expensive for the NHS.